RxDoctor Payments Data

Felipe Findley

Physician Assistant · Los Angeles, CANPI 1992823579

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $31,063 of the $51,032 with a category attached, or 60.9%. Gilead accounts for 83.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $30,595, more than ten times the $2,992 reported in 2021. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,032in general payments, 2019–2025

Across 384 payments — averaging $132.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$43K
  • Viiv Healthcare Company$7K
  • Johnson & Johnson$320
  • Neurocrine Biosciences, Inc.$252
  • Merck$245
  • Janssen Products, LP$177
  • plus $615 from 8 others

What the payments were for

  • Consulting fees$3,9208%
  • Speaking & faculty fees$31,06361%
  • Travel & lodging$6,35512%
  • Food & beverage$9,48919%
  • Education$2050%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,032 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JulucaDolutegravir/Rilpivirine73$253,206
BiktarvyBictegrav/Emtricit/Tenofov Ala56$220,240
DovatoDolutegravir Sodium/Lamivudine36$108,280
CabenuvaCabotegravir/Rilpivirine13$77,128
DelstrigoDoravirine/Lamivu/Tenofov Diso13$33,342
JardianceEmpagliflozin29$17,715
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,424
Carvedilol ErCarvedilol Phosphate12$1,802
Albuterol Sulfate HfaAlbuterol Sulfate35$1,268
Atorvastatin Calcium147$714
Ezetimibe12$437
Doxycycline Hyclate20$362
Gabapentin33$248
Metformin Hcl82$236
Amlodipine Besylate55$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Cabenuva$6,831$438,614122 claims
GileadBiktarvy$42,591$220,24056 claims
MerckDelstrigo$245$33,34213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →